CA2935867C - Heteroaryls and uses thereof - Google Patents

Heteroaryls and uses thereof Download PDF

Info

Publication number
CA2935867C
CA2935867C CA2935867A CA2935867A CA2935867C CA 2935867 C CA2935867 C CA 2935867C CA 2935867 A CA2935867 A CA 2935867A CA 2935867 A CA2935867 A CA 2935867A CA 2935867 C CA2935867 C CA 2935867C
Authority
CA
Canada
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
optionally substituted
bipyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2935867A
Other languages
English (en)
French (fr)
Other versions
CA2935867A1 (en
Inventor
Indu T. Bharathan
Chris Blackburn
Jeffrey P. Ciavarri
Jouhara CHOUITAR
Courtney A. Cullis
Natalie D'AMORE
Paul E. Fleming
Kenneth M. Gigstad
Krista E. Gipson
Mario Girard
Yongbo Hu
Janice Lee
Gang Li
Mansoureh REZAEI
Michael D. Sintchak
Francois Soucy
Stephen G. Stroud
Tricia J. Vos
Tzu-Tshin WONG
He Xu
Tianlin Xu
Yingchun Ye
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53543363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2935867(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of CA2935867A1 publication Critical patent/CA2935867A1/en
Application granted granted Critical
Publication of CA2935867C publication Critical patent/CA2935867C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2935867A 2014-01-14 2015-01-13 Heteroaryls and uses thereof Active CA2935867C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461927055P 2014-01-14 2014-01-14
US61/927,055 2014-01-14
US201462054742P 2014-09-24 2014-09-24
US62/054,742 2014-09-24
PCT/US2015/011191 WO2015108861A1 (en) 2014-01-14 2015-01-13 Heteroaryls and uses thereof

Publications (2)

Publication Number Publication Date
CA2935867A1 CA2935867A1 (en) 2015-07-23
CA2935867C true CA2935867C (en) 2023-04-04

Family

ID=53543363

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2935867A Active CA2935867C (en) 2014-01-14 2015-01-13 Heteroaryls and uses thereof

Country Status (26)

Country Link
US (3) US9802960B2 (https=)
EP (1) EP3094325B1 (https=)
JP (1) JP6609258B2 (https=)
KR (1) KR20160122736A (https=)
CN (1) CN105916503B (https=)
AP (1) AP2016009368A0 (https=)
AU (1) AU2015206652A1 (https=)
BR (1) BR112016016289B1 (https=)
CA (1) CA2935867C (https=)
CL (1) CL2016001805A1 (https=)
CR (1) CR20160363A (https=)
DO (1) DOP2016000173A (https=)
EA (1) EA032458B1 (https=)
EC (1) ECSP16067303A (https=)
ES (1) ES2908042T3 (https=)
GE (2) GEAP201914237A (https=)
IL (1) IL246755A0 (https=)
MX (1) MX2016009135A (https=)
MY (1) MY182908A (https=)
PE (1) PE20161313A1 (https=)
PH (1) PH12016501388A1 (https=)
SG (1) SG11201604820XA (https=)
TN (1) TN2016000270A1 (https=)
TW (1) TWI662024B (https=)
UY (1) UY35951A (https=)
WO (1) WO2015108861A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104230922B (zh) * 2013-06-19 2016-12-28 中国科学院上海药物研究所 一类五元杂环并吡啶类化合物及其制备方法和用途
AU2015206652A1 (en) 2014-01-14 2016-08-04 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
WO2015108881A1 (en) 2014-01-14 2015-07-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
EP3365334B1 (en) * 2015-10-21 2024-07-17 Otsuka Pharmaceutical Co., Ltd. Benzolactam compounds as protein kinase inhibitors
DK3416957T3 (da) 2016-02-19 2020-09-21 Sprint Bioscience Ab 6-heterocyclyl-4-morpholin-4-ylpyridin-2-on-forbindelser anvendelige ved behandlingen af cancer og diabetes
AU2017219846B2 (en) 2016-02-19 2021-05-13 Sprint Bioscience Ab 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes
WO2018144791A1 (en) * 2017-02-03 2018-08-09 Millennium Pharmaceuticals, Inc. Combination of vps34 inhibitors and mtor inhibitors
GB201706327D0 (en) * 2017-04-20 2017-06-07 Otsuka Pharma Co Ltd A pharmaceutical compound
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
WO2019038387A1 (en) 2017-08-23 2019-02-28 Sprint Bioscience Ab PYRIDYLPYRIDONE COMPOUNDS
US11560374B2 (en) 2017-08-23 2023-01-24 Sprint Bioscience Ab Morpholinylpyridone compounds
JP7199738B2 (ja) 2017-08-23 2023-01-06 スプリント バイオサイエンス アクティエボラーグ アザインドリルピリドンおよびジアザインドリルピリドン化合物
CN111094271B (zh) 2017-08-23 2023-02-28 思普瑞特生物科学公司 吡啶胺-吡啶酮化合物和嘧啶胺-吡啶酮化合物
US11076596B2 (en) 2017-09-18 2021-08-03 Basf Se Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi
TWI707849B (zh) 2018-02-13 2020-10-21 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
EP3820572B1 (en) 2018-07-13 2023-08-16 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
KR102328682B1 (ko) * 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
WO2020045941A1 (ko) * 2018-08-27 2020-03-05 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
CN109608444B (zh) * 2018-11-27 2022-02-11 中国药科大学 含异吲哚啉酮的erk抑制剂及其制备方法与用途
US20220324830A1 (en) * 2019-09-11 2022-10-13 Prelude Therapeutics, Incorporated CDK Inhibitors And Their Use As Pharmaceuticals
CN112574207B (zh) * 2019-09-30 2023-04-11 南京药石科技股份有限公司 Erk1/2蛋白激酶抑制剂及其用途
WO2021160109A1 (zh) * 2020-02-13 2021-08-19 劲方医药科技(上海)有限公司 二氢萘啶酮类化合物，其制法与医药上的用途
CA3199988A1 (en) 2020-11-25 2022-06-02 Daniel L. Flynn Pyridylpyridone derivatives as vsp34 inhibitors for use in the treatment of a viral infection
TWI824626B (zh) * 2021-08-02 2023-12-01 大陸商勁方醫藥科技(上海)有限公司 Ripk1抑制劑的晶型及其酸式鹽和其酸式鹽的晶型
US12319655B2 (en) 2021-12-09 2025-06-03 Deciphera Pharmaceuticals, Llc RAF kinase inhibitors and methods of use thereof
AU2023364628A1 (en) 2022-10-18 2025-04-03 Pfizer Inc. Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers
WO2024084363A1 (en) 2022-10-18 2024-04-25 Pfizer Inc. Use of patatin-like phospholipase domain-containing protein 3 compounds
GB202216324D0 (en) * 2022-11-02 2022-12-14 Cerevance Ltd Novel compounds
WO2025184010A1 (en) * 2024-03-01 2025-09-04 Merck Sharp & Dohme Llc N-biaryl sulfonamides as modulators of the hippo pathway

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006512314A (ja) 2002-11-01 2006-04-13 バーテックス ファーマシューティカルズ インコーポレイテッド Ｊａｋインヒビターおよび他のプロテインキナーゼインヒビターとしての組成物の使用
FR2850652B1 (fr) 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
SE0402735D0 (sv) 2004-11-09 2004-11-09 Astrazeneca Ab Novel compounds
EP1814856A1 (en) 2004-11-12 2007-08-08 Galapagos N.V. Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes
GB0425026D0 (en) * 2004-11-12 2004-12-15 Biofocus Discovery Ltd Compounds which bind to the active site of protein kinase enzymes
CA2591413A1 (en) * 2004-12-16 2006-06-22 Vertex Pharmaceuticals Incorporated Pyrid-2-ones useful as inhibitors of tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases
ZA200704971B (en) * 2004-12-16 2008-09-25 Vertex Pharma Pyrid-2-ones useful as inhibitors of Tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases
US7601716B2 (en) 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
WO2007135398A1 (en) 2006-05-22 2007-11-29 Astrazeneca Ab Indole derivatives
US20080280891A1 (en) 2006-06-27 2008-11-13 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
WO2008008059A1 (en) 2006-07-12 2008-01-17 Locus Pharmaceuticals, Inc. Anti-cancer agents ans uses thereof
JP5336375B2 (ja) 2006-08-30 2013-11-06 セルゾーム リミテッド キナーゼ阻害剤としてのトリアゾール誘導体
ATE507225T1 (de) 2006-12-04 2011-05-15 Astrazeneca Ab Antibakterielle polycyclische harnstoffverbindungen
CA2672518A1 (en) 2006-12-22 2008-07-03 Novartis Ag Organic compounds and their uses
UY31137A1 (es) 2007-06-14 2009-01-05 Smithkline Beecham Corp Derivados de quinazolina como inhibidores de la pi3 quinasa
ES2394126T3 (es) 2007-07-26 2013-01-22 Novartis Ag Derivados de pirimidina útiles para el tratamiento de estados inflamatorios o alérgicos
AU2008282728B2 (en) 2007-08-02 2012-04-19 Amgen Inc. Pl3 kinase modulators and methods of use
JP2010539239A (ja) 2007-09-17 2010-12-16 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害剤としてのピリドピリミジン誘導体
US20100311736A1 (en) 2007-10-22 2010-12-09 Glaxosmithkline Llc Pyridosulfonamide derivatives as p13 kinase inhibitors
AU2008343813B2 (en) 2007-12-19 2012-04-12 Amgen Inc. Inhibitors of PI3 kinase
US8343966B2 (en) 2008-01-11 2013-01-01 Novartis Ag Organic compounds
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
US8309577B2 (en) 2008-04-23 2012-11-13 Bristol-Myers Squibb Company Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands
JP5599783B2 (ja) 2008-05-30 2014-10-01 アムジエン・インコーポレーテツド Ｐｉ３キナーゼの阻害薬
ES2566339T3 (es) 2008-06-05 2016-04-12 Glaxo Group Limited Derivados de 4-carboxamida indazol útiles como inhibidores de PI3-quinasas
WO2010008847A2 (en) 2008-06-24 2010-01-21 Takeda Pharmaceutical Company Limited Pi3k/m tor inhibitors
WO2010007100A1 (en) 2008-07-15 2010-01-21 Cellzome Ltd 7-substituted amino triazoles as pi3k inhibitors
JP5693452B2 (ja) 2008-08-04 2015-04-01 シーエイチディーアイ ファウンデーション，インコーポレーテッド 特定のキヌレニン−３−モノオキシゲナーゼインヒビター、医薬組成物およびそれらの使用方法
CA2743242A1 (en) 2008-11-11 2010-05-20 Eli Lilly And Company P70 s6 kinase inhibitor and mtor inhibitor combination therapy
WO2010057877A1 (en) * 2008-11-18 2010-05-27 Cellzome Limited 7-pyridinyl- or phenyl- substituted triazolo [1, 5 -a] pyridines as pi3k inhibitors
TW201026695A (en) 2008-12-12 2010-07-16 Astrazeneca Ab Piperidine compounds and uses thereof-596
BRPI1010974A2 (pt) 2009-05-22 2019-09-24 Exelixis Inc benzoxazepinas baseada em inibidores p13k/ m tor contra doenças proliferativas
CA2767089A1 (en) 2009-07-15 2011-01-20 Abbott Laboratories Pyrrolopyridine inhibitors of kinases
JP2011033670A (ja) * 2009-07-30 2011-02-17 Sony Corp 光学ファインダユニットおよび撮像装置
WO2011026911A1 (en) * 2009-09-04 2011-03-10 Novartis Ag Bipyridines useful for the treatment of proliferative diseases
AU2010344973B2 (en) * 2010-02-05 2016-06-16 Merck Patent Gmbh Hetaryl-[1,8]naphthyridine derivatives
MX2012014537A (es) 2010-07-05 2013-02-21 Merck Patent Gmbh Derivados de bipiridilo utiles para el tratamiento de enfermedades inducidas por cinasa.
ES2550939T3 (es) 2010-07-16 2015-11-13 Nivalis Therapeutics, Inc. Nuevos compuestos de dihidropiridin-2-(1H)-ona como inhibidores de la S-nitrosoglutatión reductasa y antagonistas del receptor de la neurocinina-3
CN103209960A (zh) 2010-07-26 2013-07-17 百时美施贵宝公司 用作cyp17抑制剂的磺酰胺化合物
US8478700B2 (en) 2010-08-11 2013-07-02 Brightedge Technologies, Inc. Opportunity identification and forecasting for search engine optimization
US8859768B2 (en) 2010-08-11 2014-10-14 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
MX2013001660A (es) 2010-08-11 2013-06-03 Millenium Pharmaceuticals Inc Heteroarilos y usos de los mismos.
WO2012037108A1 (en) 2010-09-13 2012-03-22 Glaxosmithkline Llc Aminoquinoline derivatives as antiviral agents
WO2012066065A1 (en) 2010-11-17 2012-05-24 Novartis Ag Phenyl-heteroaryl amine compounds and their uses
JP2013542967A (ja) 2010-11-17 2013-11-28 ノバルティス アーゲー ３−（アミノアリール）−ピリジン化合物
AU2011346567A1 (en) 2010-12-21 2013-07-25 Novartis Ag Bi-heteroaryl compounds as Vps34 inhibitors
DK2655375T3 (en) 2010-12-23 2015-03-09 Sanofi Sa PYRIMIDINON DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF
AR085013A1 (es) * 2011-01-26 2013-08-07 Sanofi Aventis Derivados de acido 3-heteroaroilamino-propionico sustituidos y su uso como sustancias farmaceuticas
WO2012101066A1 (en) 2011-01-28 2012-08-02 Novartis Ag Pyridine biaryl amine compounds and their uses
JP2014506878A (ja) 2011-01-28 2014-03-20 ノバルティス アーゲー Ｃｄｋ９阻害剤としての置換ビ−ヘテロアリール化合物およびそれらの使用
WO2012101064A1 (en) 2011-01-28 2012-08-02 Novartis Ag N-acyl pyrimidine biaryl compounds as protein kinase inhibitors
DE102011077104A1 (de) 2011-06-07 2012-12-13 Siemens Aktiengesellschaft Verfahren zur Gewinnung von metallhaltigen Wertstoffen aus einem metallhaltige Wertstoffe enthaltenden suspensionsartigen Massestrom
KR101502500B1 (ko) 2011-07-01 2015-03-16 주식회사 엘지화학 비수 전해액 및 이를 이용한 리튬 이차전지
UA111382C2 (uk) * 2011-10-10 2016-04-25 Оріон Корпорейшн Інгібітори протеїнкінази
WO2013096630A1 (en) 2011-12-23 2013-06-27 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
EP2817292B1 (en) 2012-02-22 2019-12-18 Sanford-Burnham Medical Research Institute Sulfonamide compounds and uses as tnap inhibitors
EP2855472B1 (en) * 2012-04-05 2016-09-14 Boehringer Ingelheim International GmbH Naphthyridinone derivatives as inhibitors of cytomegalovirus dna polymerase
FR2992314B1 (fr) 2012-06-22 2015-10-16 Sanofi Sa Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique
WO2014053533A1 (en) * 2012-10-05 2014-04-10 Sanofi Use of substituted 3-heteroaroylamino-propionic acid derivatives as pharmaceuticals for prevention/treatment of atrial fibrillation
WO2014058691A1 (en) * 2012-10-08 2014-04-17 Merck Sharp & Dohme Corp. Inhibitors of irak4 activity
WO2014083327A1 (en) 2012-11-27 2014-06-05 Md Pharma Ab Adenine derivatives suitable for the treatment of (inter alia) muscular dystrophy
GB201223265D0 (en) 2012-12-21 2013-02-06 Selvita Sa Novel benzimidazole derivatives as kinase inhibitors
RU2655604C2 (ru) * 2013-01-11 2018-05-29 Фуджифилм Корпорэйшн Азотсодержащее гетероциклическое соединение или его соль
TW201444820A (zh) * 2013-03-13 2014-12-01 Abbvie Inc 吡啶ｃｄｋ９激酶抑制劑
US9242969B2 (en) * 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
WO2015108881A1 (en) 2014-01-14 2015-07-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
AU2015206652A1 (en) 2014-01-14 2016-08-04 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
UY36294A (es) * 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
US10167279B2 (en) * 2014-09-12 2019-01-01 Novartis Ag Compounds and compositions as RAF kinase inhibitors

Also Published As

Publication number Publication date
CA2935867A1 (en) 2015-07-23
JP6609258B2 (ja) 2019-11-20
US20180118762A1 (en) 2018-05-03
CN105916503B (zh) 2020-04-14
PH12016501388A1 (en) 2016-08-15
AP2016009368A0 (en) 2016-08-31
EA032458B1 (ru) 2019-05-31
DOP2016000173A (es) 2016-12-15
ES2908042T3 (es) 2022-04-27
US20170073326A1 (en) 2017-03-16
CL2016001805A1 (es) 2017-07-07
BR112016016289B1 (pt) 2023-02-07
CR20160363A (es) 2016-10-12
ECSP16067303A (es) 2017-02-24
EP3094325A1 (en) 2016-11-23
PE20161313A1 (es) 2016-12-17
JP2017503813A (ja) 2017-02-02
AU2015206652A1 (en) 2016-08-04
WO2015108861A1 (en) 2015-07-23
MY182908A (en) 2021-02-05
TW201613865A (en) 2016-04-16
TWI662024B (zh) 2019-06-11
US9751854B2 (en) 2017-09-05
MX2016009135A (es) 2016-10-05
US10538533B2 (en) 2020-01-21
CN105916503A (zh) 2016-08-31
UY35951A (es) 2015-07-31
IL246755A0 (en) 2016-08-31
SG11201604820XA (en) 2016-07-28
TN2016000270A1 (en) 2017-10-06
EP3094325B1 (en) 2021-10-13
GEAP201914237A (en) 2019-02-25
GEP20196983B (en) 2019-06-25
US20150225422A1 (en) 2015-08-13
US9802960B2 (en) 2017-10-31
EP3094325A4 (en) 2017-08-09
BR112016016289A2 (en) 2018-05-08
EA201691421A1 (ru) 2017-05-31
KR20160122736A (ko) 2016-10-24

Similar Documents

Publication Publication Date Title
CA2935867C (en) Heteroaryls and uses thereof
JP7508584B2 (ja) ＰＩ３Ｋα阻害剤およびそれらの使用
AU2014348191B2 (en) Tetrahydroquinoline compositions as BET bromodomain inhibitors
JP6898914B2 (ja) コロニー刺激因子−１受容体（ｃｓｆ−１ｒ）阻害剤
AU2009281822B2 (en) cMET inhibitors
RU2267490C2 (ru) Производные замещенного пирролопиридинона, пригодные в качестве ингибиторов фосфодиэстеразы
WO2016040184A1 (en) 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
CA3237760A1 (en) Fused heterocyclic compounds as pi3kalpha inhibitors
WO2016040185A1 (en) 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
WO2019178129A1 (en) Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
WO2020021024A1 (en) Substituted bicyclic compounds as modulators of the aryl hydrocarbon receptor (ahr)
CA2946130A1 (en) Quinoxaline compounds and uses thereof
WO2017024015A1 (en) 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2016040181A1 (en) 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040190A1 (en) 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2016040193A1 (en) 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2017001924A1 (en) Therapeutic inhibitory compouds
TW201103902A (en) Inhibitors of PI3 kinase and/or mTOR
TW201038567A (en) Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
EP2373657A1 (en) 5, 7-dihydro- 6h-pyrimido ý 5, 4-d¨ý 1¨benzazepin-6-thiones as plk inhibitors
MX2014013734A (es) Inhibidores de nampt.
EP3094326A1 (en) Heteroaryls and uses thereof
EP4313308A1 (en) Tead inhibitors and uses thereof
CA3185649A1 (en) Indole compounds as androgen receptor modulators
EP3294728A1 (en) Substituted quinoxaline derivatives

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200110

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241224

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241224

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241224

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260224